{
    "nctId": "NCT03033745",
    "officialTitle": "An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameters of Immune Globulin Subcutaneous (Human), 20% Liquid (Hizentra\u00ae) in Subjects With Primary Immunodeficiency",
    "inclusionCriteria": "* Male or female on stable dose of IgPro20 (Hizentra) therapy.\n* Women of childbearing potential must be using and agree to continue using medically approved contraception (which must be discussed with the study doctor) and must have a negative pregnancy test at screening.\n* Subjects with PID, eg, with a diagnosis of common variable immunodeficiency or X-linked agammaglobulinemia, as defined by the Pan American Group for Immune Deficiency and the European Society of Immune Deficiencies.\n* With infusion parameters as specified below:\n\nPump-Assisted Flow Rate Cohort subjects only\n\n* Experience with pump-assisted infusions of IgPro20 at the tolerated flow rate of 25 mL/h per injection site for at least 1 month prior to Day 1.\n\nPump-Assisted Volume Cohort subjects only\n\n* Total weekly IgPro20 dose of \u2265 50 mL (\u2265 10 g).\n* Experience with pump-assisted infusions of IgPro20 at tolerated volumes of 25 mL/injection site for at least 1 month prior to Day 1.\n\nManual Push Flow Rate Cohort subjects only\n\n* Experience with frequent (2-7 times per week) infusions of IgPro20 at the tolerated flow rate of approximately 0.5 mL/min (equivalent of 25-30 mL/h) per injection site for at least 1 month prior to Day 1. The dose (volume) per injection site should not exceed 25 mL.\n* Must have minimum age of 2 Years",
    "exclusionCriteria": "* Ongoing serious bacterial infections at the time of screening.\n* Other significant medical conditions that could increase the risk to the subject.\n* Females who are pregnant, breast feeding, or planning a pregnancy during the course study.\n* Participation in a study with an Investigational Medicinal Product (IMP) other than IgPro20 within three months prior to enrollment."
}